Synergistic interaction between genetics and disease on pravastatin disposition

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages 139-147

  Clarke, John D ^a   Hardwick, Rhiannon N ^a   Lake, April D ^a   Lickteig, Andrew J ^b   Goedken, Michael J ^c   Klaassen, Curtis D ^b   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Adverse drug reaction; Myopathy; Non alcoholic steatohepatitis; Statin

Indexed keywords

CHOLINE; METHIONINE; ORGANIC ANION TRANSPORTER; PRAVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SLCO1B2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG TISSUE LEVEL; ENZYME SPECIFICITY; GENE INTERACTION; GENOTYPE ENVIRONMENT INTERACTION; KIDNEY; MALE; MOUSE; MUSCLE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CHOLINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; METHIONINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLES; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PRAVASTATIN;

EID: 84902649428     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.02.021     Document Type: Article

References (41)

1. A. Gandhi, B. Moorthy, and R. Ghose Drug disposition in pathophysiological conditions Curr Drug Metab 13 2012 1327 1344
2. M. Niemi, M.K. Pasanen, and P.J. Neuvonen Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol Rev 63 2011 157 181
3. J.D. Clarke, and N.J. Cherrington Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions Expert Opin Drug Metab Toxicol 8 2012 349 360
4. M. Igel, K.A. Arnold, M. Niemi, U. Hofmann, M. Schwab, and D. Lütjohann et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin Clin Pharmacol Ther 79 2006 419 426
5. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1â̂ -5, SLCO1B1â̂ -15, and SLCO1B1â̂ -15+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 15 2005 513 522
6. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Bégaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
7. G. Fernandez, E.S. Spatz, C. Jablecki, and P.S. Phillips Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
8. W. Zhang, B.-L. Chen, V. Ozdemir, Y.-J. He, G. Zhou, and D.-D. Peng et al. SLCO1B1 521TC functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients Br J Clin Pharmacol 64 2007 346 352
9. R.A. Wilke, L.B. Ramsey, S.G. Johnson, W.D. Maxwell, H.L. McLeod, and D. Voora et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy Clin Pharmacol Ther 92 2012 112 117
10. D. Voora, S.H. Shah, I. Spasojevic, S. Ali, C.R. Reed, and B.A. Salisbury et al. The SLCO1B1â̂ -5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
11. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2010 130 133
12. R.K. Verbeeck Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 2008 1147 1161
13. A.D. Lake, P. Novak, C.D. Fisher, J.P. Jackson, R.N. Hardwick, and D.D. Billheimer et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human Non-alcoholic fatty liver disease Drug Metab Dispos 39 2011 1954 1960
14. M.D. Merrell, and N.J. Cherrington Drug metabolism alterations in Non-alcoholic fatty liver disease Drug Metab Rev 43 2011 317 334
15. C.D. Fisher, A.J. Lickteig, L.M. Augustine, R.P. Oude Elferink, D.G. Besselsen, and R.P. Erickson et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats Eur J Pharmacol 613 2009 119 127
16. R.N. Hardwick, C.D. Fisher, S.M. Street, M.J. Canet, and N.J. Cherrington Molecular mechanism of altered ezetimibe disposition in Non-alcoholic steatohepatitis Drug Metab Dispos 40 2012 450 460
17. R.N. Hardwick, and N.J. Cherrington Measuring altered disposition of xenobiotics in experimental models of liver disease Curr Protoc Toxicol Chapter 23 2012 Unit 23.1
18. C.D. Fisher, A.J. Lickteig, L.M. Augustine, J. Ranger-Moore, J.P. Jackson, and S.S. Ferguson et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of Non-alcoholic fatty liver disease Drug Metab Dispos 37 2009 2087 2094
19. D.E. Kleiner, E.M. Brunt, N.M. Van, C. Behling, M.J. Contos, and O.W. Cummings et al. Design and validation of a histological scoring system for Non-alcoholic fatty liver disease Hepatology 41 2005 1313 1321
20. R.N. Hardwick, C.D. Fisher, M.J. Canet, A.D. Lake, and N.J. Cherrington Diversity in antioxidant response enzymes in progressive stages of human Non-alcoholic fatty liver disease Drug Metab Dispos 38 2010 2293 2301
21. R.W. Sparidans, D. Iusuf, A.H. Schinkel, J.H. Schellens, and J.H. Beijnen Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates J Chromatogr B Analyt Technol Biomed Life Sci 878 2010 2751 2759
22. C.Z. Larter, and M.M. Yeh Animal models of NASH: getting both pathology and metabolic context right J Gastroenterol Hepatol 23 2008 1635 1648
23. M.J. Canet, R.N. Hardwick, A.D. Lake, A.L. Dzierlenga, J.D. Clarke, and N.J. Cherrington Modeling human non-alcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models Drug Metab Dispos 42 2014 586 595
24. C.R. Harper, and T.A. Jacobson Evidence-based management of statin myopathy Curr Atheroscler Rep 12 2010 322 330
25. H. Zaher, H.E.M. zu Schwabedissen, R.G. Tirona, M.L. Cox, L.A. Obert, and N. Agrawal et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin Mol Pharmacol 74 2008 320 329
26. D. Iusuf, R.W. Sparidans, A. van Esch, M. Hobbs, K.E. Kenworthy, and E. van de Steeg et al. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice Mol Pharm 9 2012 2497 2504
27. M.V.S. Varma, Y. Lai, B. Feng, J. Litchfield, T.C. Goosen, and A. Bergman Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions Pharm Res 29 2012 2860 2873
28. S.L. Di Stasi, T.D. MacLeod, J.D. Winters, and S.A. Binder-Macleod Effects of statins on skeletal muscle: a perspective for physical therapists Phys Ther 90 2010 1530 1542
29. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
30. R.H. Ho, L. Choi, W. Lee, G. Mayo, U.I. Schwarz, and R.G. Tirona et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants Pharmacogenet Genomics 17 2007 647 656
31. J. Mwinyi, A. Johne, S. Bauer, I. Roots, and T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin Pharmacol Ther 75 2004 415 421
32. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, and T. Hirota et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 2003 554 565
33. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, and C. Kyrklund et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
34. R. Tachibana-Iimori, Y. Tabara, H. Kusuhara, K. Kohara, R. Kawamoto, and J. Nakura et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors Drug Metab Pharmacokinet 19 2004 375 380
35. H. Takane, M. Miyata, N. Burioka, C. Shigemasa, E. Shimizu, and K. Otsubo et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy J Hum Genet 51 2006 822 826
36. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, and N.B. Wolf et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3 Drug Metab Dispos 35 2007 779 786
37. T. Nozawa, K. Imai, J.-I. Nezu, A. Tsuji, and I. Tamai Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human J Pharmacol Exp Ther 308 2004 438 445
38. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, and W.P. Yang et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J Biol Chem 274 1999 37161 37168
39. T. Tokui, D. Nakai, R. Nakagomi, H. Yawo, T. Abe, and Y. Sugiyama Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2 Pharm Res 16 1999 904 908
40. R. Ali, and K. Cusi New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) Ann Med 41 2009 265 278
41. W. Nseir, J. Mograbi, and M. Ghali Lipid-lowering agents in Non-alcoholic fatty liver disease and steatohepatitis: human studies Dig Dis Sci 57 2012 1773 1781